Diagnostic delay in amyotrophic lateral sclerosis: what scope for improvement?

J Neurol Sci

Department of Neurology, St. Bartholomew's and The Royal London School of Medicine and Dentistry, Royal London Hospital, London E1 1BB, UK.

Published: November 2000

The average time taken from symptom onset to diagnosis in motor neuron disease is many months and has shown no sign of improving despite the introduction of riluzole therapy. We performed a retrospective analysis of the time to diagnosis in 57 patients using a structured interview with the patients and/or their carers. In this cohort, studied in England and Wales, the mean time from onset to diagnosis was 16.2 months. An initial incorrect diagnosis, refusal to consider the diagnosis when it was suggested by the informed patient, failure to consider a neurological cause for the patient's symptoms, and failure to make early referral to a neurologist were the major factors leading to delayed diagnosis. Bulbar symptoms were more likely to lead to correct diagnosis than limb-onset features. Ten of our patients made the diagnosis by consulting reference books or the Internet before they were informed of it by their physician.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0022-510x(00)00418-4DOI Listing

Publication Analysis

Top Keywords

diagnosis
8
onset diagnosis
8
diagnostic delay
4
delay amyotrophic
4
amyotrophic lateral
4
lateral sclerosis
4
sclerosis scope
4
scope improvement?
4
improvement? average
4
average time
4

Similar Publications

The effect of tonsillectomy on clinical manifestations in Familial Mediterranean fever.

Int J Pediatr Otorhinolaryngol

January 2025

Otorhinolaryngology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt; Medicine and Surgery Program, Menoufia National University, Menoufia, Egypt. Electronic address:

Purpose: Familial Mediterranean fever (FMF) is the most prevalent genetic autoinflammatory disease worldwide. There are several novel advancements in pathophysiology, genetic testing, diagnosis, comorbidities, disease-related damage, and treatment strategies. This study aimed to assess the effect of tonsillectomy on FMF disease severity and activity.

View Article and Find Full Text PDF

Background: Tissue-based genomic classifiers (GCs) have been developed to improve prostate cancer (PCa) risk assessment and treatment recommendations.

Purpose: To summarize the impact of the Decipher, Oncotype DX Genomic Prostate Score (GPS), and Prolaris GCs on risk stratification and patient-clinician decisions on treatment choice among patients with localized PCa considering first-line treatment.

Data Sources: MEDLINE, EMBASE, and Web of Science published from January 2010 to August 2024.

View Article and Find Full Text PDF

Background: Depression significantly impacts an individual's thoughts, emotions, behaviors, and moods; this prevalent mental health condition affects millions globally. Traditional approaches to detecting and treating depression rely on questionnaires and personal interviews, which can be time consuming and potentially inefficient. As social media has permanently shifted the pattern of our daily communications, social media postings can offer new perspectives in understanding mental illness in individuals because they provide an unbiased exploration of their language use and behavioral patterns.

View Article and Find Full Text PDF

Background: Cognitive deterioration is common in multiple sclerosis (MS) and requires regular follow-up. Currently, cognitive status is measured in clinical practice using paper-and-pencil tests, which are both time-consuming and costly. Remote monitoring of cognitive status could offer a solution because previous studies on telemedicine tools have proved its feasibility and acceptance among people with MS.

View Article and Find Full Text PDF

To provide proof-of-concept (PoC), dose-range finding, and safety data for BI 1358894, a TRPC4/5 ion channel inhibitor, in patients with borderline personality disorder (BPD). This was a phase 2, multinational, randomized, double-blind, placebo controlled trial. Patients were randomized to oral placebo or BI 1358894 (5 mg, 25 mg, 75 mg, or 125 mg) once daily in a 2.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!